The plasminogen activation system in lung cancer — with special reference to the prognostic role in “non‐small cell lung cancer”
1999; Wiley; Volume: 107; Issue: S92 Linguagem: Inglês
10.1111/j.1600-0463.1999.tb05687.x
ISSN1600-0463
Autores Tópico(s)Ubiquitin and proteasome pathways
ResumoAPMISVolume 107, Issue S92 p. 5-29 The plasminogen activation system in lung cancer — with special reference to the prognostic role in “non-small cell lung cancer” HELLE PAPPOT MD, HELLE PAPPOT MD The Finsen Center Rigshospitalet, Copenhagen, DenmarkSearch for more papers by this author HELLE PAPPOT MD, HELLE PAPPOT MD The Finsen Center Rigshospitalet, Copenhagen, DenmarkSearch for more papers by this author First published: 12 October 2011 https://doi.org/10.1111/j.1600-0463.1999.tb05687.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat BIBLIOGRAPHY Altman DG, Lausen B., Sauerbrei W., Schumacher M. Dangers of using Aoptimal@ cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829–34. 10.1093/jnci/86.11.829 CASPubMedWeb of Science®Google Scholar Andreasen PA, Georg B., Lund LR, Riccio A., Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1–19. 10.1016/0303-7207(90)90164-4 CASPubMedWeb of Science®Google Scholar Andrén-Sandberg A., Lecander I., Martinsson G., Åstedt B. Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma. Cancer 1992; 69: 2884–2887. 10.1002/1097-0142(19920615)69:12 3.0.CO;2-S CASPubMedWeb of Science®Google Scholar Bashar H., Urano T., Fukuta K., Pietrazek MH, Hata M., Suzuka K., Kawabe K., Takada Y., Takada A. Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urology Int 1994; 52: 4–8. 10.1159/000282560 CASPubMedWeb of Science®Google Scholar Behrendt N., Rønne E., Ploug M., Petri T., Løber D., Nielsen LS, Schleuring WO, Blasi F., Appella E., Danø K. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990; 265: 6453–6460. 10.1016/S0021-9258(19)39348-2 CASPubMedWeb of Science®Google Scholar Benraad TJ, Geurts-Moespot J., Grøndahl-Hansen J., Schmitt M., Hewel J., de Witte JH, Foekens JA, Leake RE, Brünner N., Sweep C. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop. Eur J of Cancer 1996; 32A: 1371–1381. 10.1016/0959-8049(96)00118-9 CASPubMedWeb of Science®Google Scholar Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opi Cell Biol 1995; 7: 728–735. 10.1016/0955-0674(95)80116-2 CASPubMedWeb of Science®Google Scholar Blasi F., Vassalli JD, Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801–804. 10.1083/jcb.104.4.801 CASPubMedWeb of Science®Google Scholar Bolon I., Gouyer V., Devouassoux M., Vandenbunder B., Wernert N., Moro D., Brambilla C., Brambilla E. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 1995; 147: 1298–1310. CASPubMedWeb of Science®Google Scholar Bouchet C., Spyratos F., Martin PM, Hacene K., Gentile A., Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994; 69: 398–405. 10.1038/bjc.1994.74 CASPubMedWeb of Science®Google Scholar Boyle P. Cancer, Cigarette Smoking and Premature Death in Europe. A review. Lung Cancer 1997; 17: 1–60. 10.1016/S0169-5002(97)00648-X CASPubMedWeb of Science®Google Scholar Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen dificency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794–807. 10.1101/gad.9.7.794 CASPubMedWeb of Science®Google Scholar Camiolo SM, Siuta MR, Madeja JM. Improved medium for extraction of plasminogen activator from tissue. Preparative Biochemistry 1982; 12: 297–305. 10.1080/00327488208065678 CASPubMedWeb of Science®Google Scholar Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., de Vos R., van den Oord JJ, Collen D., Michigan RL. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419–424. 10.1038/368419a0 CASPubMedWeb of Science®Google Scholar Carney DN, Gazdar AF, Nau M., Minna JD. Biological heterogeneity of small cell lung cancer. Semin Oncol 1985; 12: 289–303. CASPubMedWeb of Science®Google Scholar Casslén B., Bossmar T., Leander I., Åstedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J of Cancer 1994; 30A: 1302–1309. 10.1016/0959-8049(94)90178-3 CASPubMedWeb of Science®Google Scholar Colby TV, Koss MN, Travis WD. Atlas of tumor pathology: Tumors of the lower respiratory tract. Armed Forces Institute of Pathology, Washington, D.C. 1995. Web of Science®Google Scholar Collen D., Lijnen HR, Todd PA, Goa KL. Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 1989; 38: 346–388. 10.2165/00003495-198938030-00003 CASPubMedWeb of Science®Google Scholar Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; 187: 187–220. Google Scholar Crowley CW, Cohen RL, Lucas BK, Liu G., Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A 1993; 90: 5021–5025. 10.1073/pnas.90.11.5021 CASPubMedWeb of Science®Google Scholar Danø K., Andreasen PA, Grøndahl-Hansen J., Kristensen P., Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139–266. 10.1016/S0065-230X(08)60028-7 CASPubMedWeb of Science®Google Scholar Danø K., Behrendt N., Brünner N., Ellis V., Ploug M., Pyke C. The urokinase receptor. Protein Structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8: 189–203. 10.1016/0268-9499(94)90717-X Web of Science®Google Scholar Deng G., Curriden SA, Rosenberg S., Loskutoff D. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor mediated cell adhesion and release J Cell Biol 1996; 134: 1–9. 10.1083/jcb.134.6.1563 PubMedWeb of Science®Google Scholar de Witte JH, Pappot H., Brünner N., Grøndahl-Hansen J., Høyer-Hansen G., Behrendt N., Skov BG, Sweep CGJ, Benraas T., Danø K. An ELISA for measurement of complexes of urokinase-type plasminogen activator with its receptor in lung cancer tissue extracts. Int J of Cancer 1997; 72: 416–423. 10.1002/(SICI)1097-0215(19970729)72:3 3.0.CO;2-S PubMedWeb of Science®Google Scholar Duffy MJ, Reilly D., O'Sullivan C., O'Higgins N., Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827–6829. CASPubMedWeb of Science®Google Scholar Ebert W., Knoch H., Werle B., Trefz G., Muley T., Spiess E. Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res 1994; 14: 895–899. PubMedWeb of Science®Google Scholar Ehlers MR, Riordan JF. Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. Biochemistry 1991; 30: 10065–10074. 10.1021/bi00106a001 CASPubMedWeb of Science®Google Scholar Ellis V., Danø K. Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemost 1991; 17: 194–200. 10.1055/s-2007-1002609 PubMedWeb of Science®Google Scholar Ellis V., Pyke C., Eriksen J., Solberg H., Danø K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci 1992; 667: 13–31. 10.1111/j.1749-6632.1992.tb51591.x CASPubMedWeb of Science®Google Scholar Foekens JA, Schmitt M., van Putten WL, Peters HA, Bontenbal M., Jänicke F., Klijn JG. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101–6105. CASPubMedWeb of Science®Google Scholar Foekens JA, Schmitt M., van Putten WLJ, Peters HA, Kramer MD, Jänicke F., Klijn JGM. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648–1658. 10.1200/JCO.1994.12.8.1648 CASPubMedWeb of Science®Google Scholar Foekens JA, Buessecker F., Peters HA, Krainick U., van Putten WLJ, Look MP, Klijn JGM, Kramer MD. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423–1427. CASPubMedWeb of Science®Google Scholar Ganesh S., Sier CF, Griffioen G., Vloedgraven HJ, de Boer A., Welvaart K., van de Velde CJ, van Krieken JH, Verheijen J., Lamers CB et al.. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065–4071. CASPubMedWeb of Science®Google Scholar Ganesh S., Sier CFM, Heerding MM, Griffioen G., Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344: 401–402. 10.1016/S0140-6736(94)91427-3 CASPubMedWeb of Science®Google Scholar Greenblatt MS, Bennett WP, Hollstein M., Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–4878. CASPubMedWeb of Science®Google Scholar Gris JC, Schved JF, Double MC, Mauboussin JM, Balmes P. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Chest 1993; 104: 8–13. 10.1378/chest.104.1.8 CASPubMedWeb of Science®Google Scholar Grøndahl-Hansen J., Agerlin N., Larsen Munkholm P., Bach F., Nielsen LS, Dombernovsky P., Danø K. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988; 111: 42–51. PubMedWeb of Science®Google Scholar Grøndahl-Hansen J., Christensen IJ, Rosenquist C., Brünner N., Mouridsen HT, Danø K., Blichert Toft et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513–2521. CASPubMedWeb of Science®Google Scholar Grøndahl-Hansen J., Peters HA, van Putten WLJ, Look MP, Pappot H., Rønne E., Danø K., Klijn JGM, Brünner N., Foekens JA. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079–1087. CASPubMedWeb of Science®Google Scholar Grøndahl-Hansen J., Christensen IJ, Briand P., Pappot H., Mouridsen HT, Blichert-Toft M., Danø K., Brünner N. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low risk breast cancer patients. Clin Cancer Res 1997; 3: 233–239. CASPubMedWeb of Science®Google Scholar Hansen H. Textbook for General Practioners: Lung Cancer, EEC Monograph (Springer-Verlag, Berlin 1991). Google Scholar Hansen HH. Management of small-cell cancer of the lung. Lancet 1992; 339: 846–849. 10.1016/0140-6736(92)90287-D CASPubMedWeb of Science®Google Scholar Harpole DH, Jr., Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55: 51–56. CASPubMedWeb of Science®Google Scholar Hasui Y., Marutsuka K., Nishi S., Kitada S., Osada Y., Sumiyoshi A. The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 1994; 151: 16–19. 10.1016/S0022-5347(17)34861-9 CASPubMedWeb of Science®Google Scholar Hekman CM, Loskutoff DJ. Bovine plasminogen activator inhibitor 1: specificity determinations and comparision of the active, latent and guanidine-activated forms. Biochemistry 1988; 27: 2911–2918. 10.1021/bi00408a037 CASPubMedWeb of Science®Google Scholar Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Nimi T., Shimokata K., Yamakawa K., Nakamura Y., Ueda K. et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993; 53: 1–4. CASPubMedWeb of Science®Google Scholar Høyer-Hansen G., Rønne E., Solberg H., Behrendt N., Ploug M., Lund LR, Ellis V., Danø K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267: 18224–18229. 10.1016/S0021-9258(19)37176-5 CASPubMedWeb of Science®Google Scholar Inoue T., Ishida T., Sugio K., Sugimachi K. Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. Cancer Res 1994; 54: 6133–6136. CASPubMedWeb of Science®Google Scholar Ishida T., Sugio K., Yokoyama K., Teteishi M., Oka T., Sugimachi K. Immunohistochemical evidences of prognostic parameters associated with tumor development of pulmonary adenocarcinoma. Nippon Geka Gakkai Zasshi 1991; 92: 1107–1110. CASPubMedGoogle Scholar Jänicke F., Schmitt M., Hafter R., Hollrieder A., Babie R., Ulm K., Gössner W., Graeff H. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4: 69–78. 10.1016/0268-9499(90)90001-Z Web of Science®Google Scholar Jänicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Haemostasis 1991; 17: 303–312. 10.1055/s-2007-1002624 CASPubMedWeb of Science®Google Scholar Jänicke F., Pache L., Schmitt M., Ulm K., Thomssen C., Prechtl A., Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994; 54: 2527–2530. CASPubMedWeb of Science®Google Scholar Jensen OM, Esteve J., Møller H., Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167–1256. 10.1016/0277-5379(90)90278-2 CASPubMedWeb of Science®Google Scholar Kluft C., Verheijen JH. Leiden Fibrinolysis Working Party: Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 1990; 4: 155–161. 10.1016/0268-9499(90)90397-3 CASWeb of Science®Google Scholar Koshland DEJ. Molecule of the year (editorial). Science 1993; 262: 1953. 10.1126/science.8266084 PubMedWeb of Science®Google Scholar Kristensen P., Pyke C., Lund LR, Andreasen PA, Danø K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 1990; 93: 559–566. 10.1007/BF00272198 CASPubMedWeb of Science®Google Scholar Kruithof EKO. Plasminogen activator inhibitors — a review. Enzyme 1988; 40: 113–121. 10.1159/000469153 CASPubMedWeb of Science®Google Scholar Kuhn W., Pache L., Schmalfeldt B., Dettmar P., Schmitt M., Jänicke F., Graeff H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGOIII) after radical surgery and platinum-based chemotherapy. Gy Oncol, in press. Google Scholar Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15–16. 10.1038/358015a0 CASPubMedWeb of Science®Google Scholar Lane DP. Cancer. A death in the life of p53. Nature 1993; 362: 786–787. 10.1038/362786a0 CASPubMedWeb of Science®Google Scholar Lane DP. The regulation of p53 function: Steiner Award Lecture. Int J Cancer 1994; 57: 623–627. 10.1002/ijc.2910570502 CASPubMedWeb of Science®Google Scholar Ledermann JA, Souhami RL. Biology of lung cancer. Curr Opin Oncol 1993; 5: 294–301. 10.1097/00001622-199303000-00008 CASPubMedGoogle Scholar Liotta LA, Steeg PS. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–336. 10.1016/0092-8674(91)90642-C CASPubMedWeb of Science®Google Scholar Lipford EH, 3d, Eggleston JC, Lillemoe KD, Sears DL, Moore GW, Baker RR. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol 1984; 8: 357–365. 10.1097/00000478-198405000-00004 PubMedWeb of Science®Google Scholar Markus G., Takita H., Camiolo SM, Corasanti JG, Evers JL, Hobika GH. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res 1980; 40: 841–848. CASPubMedWeb of Science®Google Scholar McLaren R., Kuzu I., Dunnill M., Harris A., Lane D., Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992; 66: 735–738. 10.1038/bjc.1992.348 CASPubMedWeb of Science®Google Scholar Meijer P., Pollet DE, Wauters J., Kluft C. Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest Plasminogen activator inhibitor-1 immunoassay evaluated. Clin Chem 1994; 40: 110–115. CASPubMedWeb of Science®Google Scholar Minna JD. The molecular biology of lung cancer pathogenesis. Chest 1993; 103: 449S–456S. 10.1378/chest.103.4_Supplement.449S CASPubMedGoogle Scholar Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer [see comments]. J Natl Cancer Inst 1993; 85: 2018–2023. 10.1093/jnci/85.24.2018 CASPubMedWeb of Science®Google Scholar Mørkve O., Halvorsen OJ, Skjærven R., Stangeland L., Gulsvik A., Lærum OD. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res 1993; 13: 571–578. CASPubMedWeb of Science®Google Scholar Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 225S–233S. 10.1378/chest.89.4_Supplement.225S CASPubMedWeb of Science®Google Scholar Mountain CF. Prognostic implications of the International Staging System for Lung Cancer. Semin Oncol 1988; 15: 236–245. CASPubMedWeb of Science®Google Scholar Mountain CF. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest 1995; 108: 246–254. 10.1378/chest.108.1.246 CASPubMedWeb of Science®Google Scholar Mulcahy HE, Duffy MJ, Gibbons D., McCarthy P., Parfray NA, ÓDonoghue DP, Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 344: 583–584. 10.1016/S0140-6736(94)91968-2 PubMedWeb of Science®Google Scholar Nagayama M., Sato A., Hayakawa H., Urano T., Takada Y., Takada A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 1994; 73: 1398–1405. 10.1002/1097-0142(19940301)73:5 3.0.CO;2-9 CASPubMedWeb of Science®Google Scholar Nakstad B., Lyberg T. Immunohistochemical localization of coagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung. APMIS 1991; 99: 981–988. 10.1111/j.1699-0463.1991.tb01288.x CASPubMedWeb of Science®Google Scholar Nekarda H., Schmitt M., Ulm K., Weninger A., Vogelsang H., Becher K., Roder JD, Fin U., Siewert RJ. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54: 2900–2907. CASPubMedWeb of Science®Google Scholar Nykjær A., Petersen CM, Møller B., Jensen PH, Moestrup SK, Holtet TL, Etzerodt M., Thøgersen HC, Munck M., Andreasen PA. Purified alfa-2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that the alfa-2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992; 267: 14543–14546. CASPubMedWeb of Science®Google Scholar Oka T., Ishida T., Nishino T., Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res 1991; 51: 3522–3525. CASPubMedWeb of Science®Google Scholar Olson D., Polännen J., Høyer-Hansen G., Rønne E., Sakaguchi K., Wun TC, Appella E., Danø K., Blasi F. Internalization of the urokinase plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 1992; 267: 9129–9133. CASPubMedWeb of Science®Google Scholar Ornstein DL, Zacharski LR, Memoli VA, Kisiel W., Kudryk BJ, Hunt J., Rousseau SM, Stump DC. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer 1991; 68: 1061–1067. 10.1002/1097-0142(19910901)68:5 3.0.CO;2-D CASPubMedWeb of Science®Google Scholar Ossowski L., Biegel D., Reich E. Mammary plasminogen activator correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 1979; 16: 929–940. 10.1016/0092-8674(79)90108-9 CASPubMedWeb of Science®Google Scholar Ossowski L., Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611–619. 10.1016/0092-8674(83)90093-4 CASPubMedWeb of Science®Google Scholar Ossowski L., Clunie G., Masucci MT, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991a; 115: 1107–1112. CASPubMedWeb of Science®Google Scholar Ossowski L., Payne HR, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991b; 51: 274–281. CASPubMedWeb of Science®Google Scholar Passlick B., Izbicki JR, Haussinger K., Thetter O., Pantel K. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995; 109: 1205–1211. 10.1016/S0022-5223(95)70204-0 CASPubMedWeb of Science®Google Scholar Pedersen AN, Høyer-Hansen G., Brünner N., Clark GM, Larsen B., Poulsen HS, Danø K., Stephens RW. The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantified by ELISA. J Immun Methods 1997; 203: 55–65. 10.1016/S0022-1759(97)00008-2 CASPubMedWeb of Science®Google Scholar Pedersen N., Schmitt M., Rønne E., Nicoletti MI, Høyer-Hansen G., Conese M., Giavazzi R., Danø K., Kuhn W., Jänicke F. et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993; 92: 2160–2167. 10.1172/JCI116817 CASPubMedWeb of Science®Google Scholar Petersen LC, Lund LR, Nielsen LS, Danø K., Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988; 263: 11189–11195. 10.1016/S0021-9258(18)37940-7 CASPubMedWeb of Science®Google Scholar Ploug M., Behrendt N., Løber D., Danø K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb He-most 1991a; 17: 183–193. 10.1055/s-2007-1002608 PubMedWeb of Science®Google Scholar Ploug M., Rønne E., Behrendt N., Jensen AL, Blasi F., Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991b; 266: 1926–1933. 10.1016/S0021-9258(18)52382-6 CASPubMedWeb of Science®Google Scholar Ploug M., Eriksen J., Plesner T., Hansen NE, Danø K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem 1992; 208: 397–404. 10.1111/j.1432-1033.1992.tb17200.x CASPubMedWeb of Science®Google Scholar Pyke C., Kristensen P., Ralfkiær E., Eriksen J., Danø K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991a; 51: 4067–4071. CASPubMedWeb of Science®Google Scholar Pyke C., Kristensen P., Ralfkiær E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991b; 138: 1059–1067. CASPubMedWeb of Science®Google Scholar Pyke C., Gram N., Ralfkiær E., Rønne E., Høyer-Hansen G., Brünner N., Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993; 53: 1911–1915. CASPubMedWeb of Science®Google Scholar Pyke C., Ralfkiær E., Rønne E., Høyer-Hansen G., Kirkeby L., Danø K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994a; 24: 131–138. 10.1111/j.1365-2559.1994.tb01291.x CASPubMedWeb of Science®Google Scholar Pyke C. Histological investigation of human metastazing tumors for components of the plasminogen activation system. 1994b;1–30 ( Thesis, University of Copenhagen). Google Scholar Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828–4831. CASPubMedWeb of Science®Google Scholar Rømer J., Bugge TH, Pyke C., Lund LR, Flick MJ, Degen JL, Danø K. Impaired wound healing in mice with a disrupted plasminogen gene. Nature med 1996; 2: 287–292. 10.1038/nm0396-287 PubMedWeb of Science®Google Scholar Rønne E., Høyer-Hansen G., Brünner N., Pedersen H., Rank F., Osborne CK, Clark GM, Danø K., Grøndahl-Hansen J. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 1995a; 33: 199–207. 10.1007/BF00665944 CASPubMedWeb of Science®Google Scholar Rønne E., Pappot H., Grøndahl-Hansen J., Høyer-Hansen G., Plesner T., Hansen NE, Danø K. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995b; 89: 576–581. 10.1111/j.1365-2141.1995.tb08366.x CASPubMedWeb of Science®Google Scholar Rosenquist C., Thorpe SM, Danø K., Grøndahl-Hansen J. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat 1993; 28: 223–229. 10.1007/BF00666583 CASPubMedWeb of Science®Google Scholar Schnipper LE. Clinical inplications of tumor-cell heterogeneity. N Engl J Med 1986; 314: 1423–1431. 10.1056/NEJM198605293142206 CASPubMedWeb of Science®Google Scholar Shimada H., Ikeuchi M., Suwa M., Mishimoto T., Oka Y., Tuada S., Himuro K., Hoshino T., Takushima E. Study on the plasma plasminogen activators in patients with malignant gynecologic tumors. Nippon Sanka Fujinka Gakkai Zasshi 1989; 41: 1353–1359. CASPubMedGoogle Scholar Shulman M., Wilde CD, Köhler GA. A better cell line for making hybridomas secreting specific antibodies. Nature 1978; 278: 269–270. 10.1038/276269a0 PubMedWeb of Science®Google Scholar Solberg H., Rømer J., Brünner N., Holm A., Sidenius N., Danø K., Høyer-Hansen G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 1994; 58: 877–881. 10.1002/ijc.2910580622 CASPubMedWeb of Science®Google Scholar Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJAG, Høyer-Hansen G., Rønne E., Dybkjær E., Danø K., Brünner N. ELISA determinations of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chemistry, 1997; 43: 1868–1876. CASPubMedWeb of Science®Google Scholar Storm HM, Sprøgel T. Cancer Incidence in Denmark 1987 (Danish Cancer Society, Copenhagen 1990). Google Scholar Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 1995; 13: 1265–1279. 10.1200/JCO.1995.13.5.1265 CASPubMedWeb of Science®Google Scholar Strickland S., Reich E., Sherman MI. Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell 1976; 9: 231–240. 10.1016/0092-8674(76)90114-8 CASPubMedWeb of Science®Google Scholar The World Health Organization. The World Health Organization Histological Typing of Lung Tumours. Second Edition. Am J Clin Pathol 1983; 77: 123–126. Google Scholar Thorpe SM, Rochefort H., Garcia M., Freiss G., Christensen IJ, Khalof S., Paolucci F., Pau B., Rasmussen BB, Rose C. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49: 6008–6014. CASPubMedWeb of Science®Google Scholar van Zandwijk N., Mooi WJ, Rodenhuis S. Prognostic factors in NSCLC. Recent experiences. Lung Cancer 1995; 12 Suppl 1: S27–33. 10.1016/0169-5002(95)00418-Z PubMedWeb of Science®Google Scholar Volm M., Mattern J. Immunohistochemical detection of p53 in non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 1249. 10.1093/jnci/86.16.1249 CASPubMedWeb of Science®Google Scholar Winter SF, Minna JD, Johnson BE, Takahashi T., Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168–4174. CASPubMedWeb of Science®Google Scholar Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W., Kudyk BJ, Rousseau SM, Stump DC. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990; 65: 481–485. 10.1002/1097-0142(19900201)65:3 3.0.CO;2-U PubMedWeb of Science®Google Scholar Volume107, IssueS92May 1999Pages 5-29 ReferencesRelatedInformation
Referência(s)